Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01457430 · ClinicalTrials.gov registry record · Phase 4
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT01457430: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01457430 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01457430, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of angioedema will not change the time to complete or near complete resolution of symptoms compared to treatment with Icatibant in a medical facility.
Interventions
- DRUG Icatibant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01457430
The ClinicalTrials.gov registry entry for NCT01457430 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Icatibant is the first listed.
NCT01457430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01457430 about?
NCT01457430 is a clinical study titled "Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE". The investigators propose a study to evaluate the safety, local tolerability, convenience, and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary angioedema. The investigators believe that self administration with Icatibant for treatment of an acute attack of an...
What is the current status of trial NCT01457430?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2011-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01457430?
The interventions under investigation include: Icatibant (DRUG).
Who is sponsoring clinical trial NCT01457430?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.